Neuronal Potassium Channel Openers Flupirtine (SNEPCO) in the Treatment of the Pharmacoresistant Epilepsy

Abstract

IntroductionFlupirtine is used in many European countries for the treatment of different pain states because of its analgesic attributes. It is a centrally acting, non-opioid analgesic.ObjectiveThe aim of the study was to investigate an entire study the possibility of applying flupirtine (ktadolona) – selective neuronal potassium channel activators in the treatment of pharmacoresistant epilepsy and related non-psychotic depressive disorder in adults.Material and methodsA total of 20 patients with the diagnosis of primary – generalized idiopathic epilepsy (IGE) and “non-psychotic depressive disorder due to epilepsy (F06.362)”. Before applying katadolon forte, patients received standard antiepileptic and antidepressant drugs (Depakine-Chrono 1000 mg/day, 150 mg lamotrigine/day, levitiratsetam 3000 mg/day of citalopram 20 mg/day). Assigning a first katadolon fote 14 days 200 mg 2 times a day, followed by 200 mg three in day inside.ResultsOf the 20 patients, 10 had no seizures, 8 marked decrease in the frequency of seizures in 2 patients therapy was not effective.ConclusionOur data should be considered preliminary, because small sample of patients and duration of follow-up (18 months). The next phase of work will be carried out on a large sample of patients and a longer observation, placebo – controlled, double blind study.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Neuronal Potassium Channel Openers Flupirtine (SNEPCO) in the Treatment of the Alcohol Withdrawal without Psychiatric Comorbidity Randomized, Double-Blind, Placebo-Controlled Study

“…Analysis of statistical significance was carried out with criteria of the alternative changes. Indicates significant this has led us to investigate other potential pharmacotherapies, in particular the anticonvulsant Flupirtine [20]. Flupirtine acts at the presynaptic membrane to reduce the release of glutamate, and it has been shown to reverse depersonalization-related phenomena induced by the NMDA receptor antagonist ketamine in a healthy individual.…”